Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01881113 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
A Phase 3 study of Allergic Conjunctivitis, sponsored by Aciex Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT01881113: Completed Phase 3 study of Allergic Conjunctivitis, sponsored by Aciex Therapeutics.
NCT01881113 is a Phase 3 study of Allergic Conjunctivitis that has completed, run by Aciex Therapeutics. The registered enrollment target is 101 participants, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01881113, a Phase 3 study of Allergic Conjunctivitis, has completed, sponsored by Aciex Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
Primary Outcome
A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
Conditions Studied
Interventions
- DRUG AC-170 0.24%
- DRUG AC-170 0%
Study Locations (1)
Massachusetts
- Ora, Inc. - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
What the finished NCT01881113 record still lists
NCT01881113 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which AC-170 0.24% is the first listed.
NCT01881113 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01881113 about?
NCT01881113 is a clinical study titled "A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle". The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
What is the current status of trial NCT01881113?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2013-06. Estimated completion is 2013-10.
What conditions does trial NCT01881113 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01881113?
The interventions under investigation include: AC-170 0.24% (DRUG), AC-170 0% (DRUG).
Who is sponsoring clinical trial NCT01881113?
This trial is sponsored by Aciex Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01881113 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01881113's enrollment target sits among peer trials
101 10th of 20 higher than 10 of 20 other Allergic Conjunctivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Conjunctivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
COMPLETED · Phase 3
-
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
COMPLETED · Phase 3
-
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
COMPLETED · Phase 3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia